The Law Offices of Frank R. Cruz reminds investors of the upcoming April 21, 2026 deadline to participate as a lead plaintiff in the securities fraud class action lawsuit filed on behalf of investors who acquired Corcept Therapeutics Incorporated (“Corcept” or the “Company”) (NASDAQ: CORT) common stock between October 31, 2024 and December 30, 2025, inclusive (the “Class Period”).

IF YOU ARE AN INVESTOR WHO LOST MONEY ON CORCEPT THERAPEUTICS INCORPORATED (CORT), CLICK HERE TO PARTICIPATE IN THE SECURITIES FRAUD LAWSUIT.

What Happened?

On December 31, 2025, Corcept announced the U.S. Food and Drug Administration (“FDA”) had issued a Complete Response Letter (“CRL”), declining to approve the Company’s New Drug Application (“NDA”) for relacorilant as a treatment for patients with hypercortisolism, stating that the FDA had “concluded it could not arrive at a favorable benefit-risk assessment for relacorilant without Corcept providing additional evidence of effectiveness.” The Company stated it was “surprised and disappointed by this outcome.”

On this news, Corcept’s stock price fell $35.40 per share, or 50.42%, to close at $34.80 per share on December 31, 2025.

Then, on January 30, 2026, the FDA published an updated CRL regarding Corcept’s relacorilant NDA. The letter revealed that “[d]uring the pre-submission meetings, [the FDA] informed [Corcept] on several occasions of [its] concerns about the adequacy of the clinical development program to assess the effect of relacorilant” and “to expect significant review issues if [Corcept] were to submit [its] application.”

What Is The Lawsuit About?

The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) the FDA had told Corcept that it had concerns about the adequacy of the program assessing relacorilant’s effectiveness in treating hypertension in patients with hypercortisolism, including the design of its pivotal “GRACE” trial study; (2) the FDA had further told Corcept to expect significant issues with the review if Corcept was to submit the NDA; and (3) as a result, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times.

If you purchased or otherwise acquired Corcept common stock between October 31, 2024 and December 30, 2025, the deadline to seek appointment as the lead plaintiff in the securities fraud class action is April 21, 2026.

Contact Us To Participate or Learn More:

If you wish to learn more about this class action, or if you have any questions concerning this announcement or your rights or interests with respect to the pending class action lawsuit, please contact us:
Frank R. Cruz
The Law Offices of Frank R. Cruz,
2121 Avenue of the Stars, Suite 800,
Century City, California 90067
Email us at: info@frankcruzlaw.com
Call us at: 310-914-5007
Visit our website at www.frankcruzlaw.com
Follow us for updates on Twitter: twitter.com/FRC_LAW

If you inquire by email, please include your mailing address, telephone number, and number of shares purchased.

To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260416869608/en/